From Wikipedia, the free encyclopedia
  (Redirected from TC-5619)
Jump to: navigation, search
Systematic (IUPAC) name
N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
Clinical data
Legal status
CAS number 639489-84-2
ATC code ?
PubChem CID 16727410
UNII UM3821998K YesY
Synonyms TC-5619
Chemical data
Formula C22H23N3O2 
Mol. mass 361.437 g/mol
 YesY (what is this?)  (verify)

Bradanicline (TC-5619) is an experimental pharmaceutical drug being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and is currently being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [1] Phase I clinical trials have been completed successfully, and it is currently in Phase II trials.[2]

In May 2011, AstraZeneca declined to exercise its right to license the compound.[3] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[4] It is currently being studied for cognitive and memory enhancement.[5]